Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is designed as two sequential trials. The first is a phase I open label trial to
evaluate the safety and tolerability of MAT2203. The maximal tolerated and non-toxic daily
dose,will then be moved forward into a multi-day safety trial. The Phase II trial will
investigate toxicity and early fungicidal activity (EFA) of MAT2203 with flucytosine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Matinas BioPharma Nanotechnologies, Inc.
Collaborators:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute